Brief: Ascelia Pharma Opens Five Sites In Phase III Study

Ascelia Pharma AB

13/01/2020 14:51

Jan 13 (Reuters) - Ascelia Pharma AB  ACELP.ST :
    * FIVE SITES NOW OPENED IN THE PIVOTAL PHASE III CLINICAL
STUDY
SPARKLE FOR LEAD DRUG CANDIDATE MANGORAL
    * ENROLMENT OF FIRST PATIENT IS EXPECTED SHORTLY.
    * ASCELIA PHARMA EXPECTS TOP LINE RESULTS TO BE OBTAINED BY
END OF
2020 OR BEGINNING OF 2021

Source text for Eikon:  ID:nWkr4Vmq2g 
Further company coverage:  ACELP.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))